These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35796952)

  • 1. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
    Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
    ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
    Tang Y; Sang H
    Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
    Krittayaphong R; Permsuwan U
    Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
    Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
    Hallinen T; Kivelä S; Soini E; Harjola VP; Pesonen M
    Clinicoecon Outcomes Res; 2023; 15():1-13. PubMed ID: 36636485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE
    Fauchier L; Lamblin N; Tardu J; Bellier L; Groyer H; Ittah D; Chollet J; Linden S; Levy P
    Pharmacoecon Open; 2024 Jan; 8(1):19-30. PubMed ID: 37606866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
    Lou Y; Hu T; Huang J
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.
    Kim ES; Park SK; Youn JC; Lee HS; Lee HY; Cho HJ; Choi JO; Jeon ES; Lee SE; Kim MS; Kim JJ; Hwang KK; Cho MC; Chae SC; Kang SM; Park JJ; Choi DJ; Yoo BS; Cho JY; Kim KH; Oh BH; Greenberg B; Baek SH
    J Korean Med Sci; 2024 Jan; 39(1):e8. PubMed ID: 38193327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction.
    Nguyen BN; Mital S; Bugden S; Nguyen HV
    Int J Cardiol; 2023 Apr; 376():83-89. PubMed ID: 36736672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
    Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Reifsnider OS; Rakonczai P; Stargardter M; Murata T; Hirase T; Nitta D
    J Cardiol; 2023 Jun; 81(6):522-530. PubMed ID: 36858174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
    Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
    Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Zhou J; Liew D; Kaye DM; Zoungas S; Stub D
    Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008638. PubMed ID: 36252135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region.
    Liao CT; Yang CT; Kuo FH; Lee MC; Chang WT; Tang HJ; Hua YM; Chang HY; Chen ZC; Strong C; Ou HT; Toh HS
    Front Cardiovasc Med; 2021; 8():750381. PubMed ID: 34778407
    [No Abstract]   [Full Text] [Related]  

  • 17. A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials.
    García-Moll X; Croci F; Solé A; Hartgers-Gubbels ES; Calleja-Hernández MA
    Expert Rev Cardiovasc Ther; 2024; 22(1-3):131-139. PubMed ID: 38416135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
    Tafazzoli A; Reifsnider OS; Bellanca L; Ishak J; Carrasco M; Rakonczai P; Stargardter M; Linden S
    Eur J Health Econ; 2023 Dec; 24(9):1441-1454. PubMed ID: 36463524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.
    Krittayaphong R; Yadee J; Permsuwan U
    Clinicoecon Outcomes Res; 2019; 11():767-777. PubMed ID: 31824183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
    Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
    Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.